Building on her background in biochemistry, Olivia has worked on a range matters predominantly in the life sciences sector, including patent infringement and invalidity proceedings and issues surrounding Supplementary Protection Certificates (SPCs).

Previous cases have related to small molecules, antibody technology and medical devices.

Olivia has experience of proceedings before the High Court, the Court of Appeal, the Unified Patent Court and the Court of Justice of the European Union, as well as co-ordinating multi-jurisdictional litigation in Europe and Asia.

Some of Olivia’s recent work highlights include:

• Celltrion v Genentech & Novartis – litigation in the High Court relating to XOLAIR (omalizumab) formulation.
• Teva and Samsung Bioepis v Novartis – litigation in the High Court relating to LUCENTIS (ranibizumab) pre-filled syringes, also multi-jurisdictional coordination.
• Teva v Janssen – SPC litigation in the High Court relating to a treatment for schizophrenia.
• Sandoz v Searle (Janssen) – SPC litigation in the High Court, Court of Appeal and Court of Justice of the European Union relating to a treatment for HIV.
• Merck Sharp & Dohme v Shionogi – litigation in the High Court relating to a treatment for HIV.